Tevimbra (tislelizumab-jsgr) — Medica

Initial criteria

• age ≥ 18 years
• recurrent, unresectable, oligometastatic, or metastatic disease
• ONE of the following: (i) BOTH of: used for first-line treatment and used in combination with cisplatin and gemcitabine; OR (ii) BOTH of: used for subsequent treatment AND ONE of: used as single agent OR used in combination with cisplatin and gemcitabine
• prescribed by or in consultation with an oncologist

Approval duration

1 year